Abstract:
A multiparticulate dosage form formulated to make misuse more difficult containing least one active substance with potential for misuse (A), at least one synthetic or natural polymer (C), optionally at least one natural, semi-synthetic or synthetic wax (D), at least one disintegrant (E) and optionally one or more additional physiologically compatible excipients (B), wherein the individual particles of the dosage form display a breaking strength of at least 500 N and a release of active substance of at least 75% after 45 minutes measured according to Ph.Eur. in the paddle mixer with sinker in 600 ml of aqueous buffer solution with a pH value of 1.2 at 37° C. and 75 rpm.

Description:
CROSS REFERENCE TO RELATED APPLICATION 
     This application claims priority from Federal Republic of Germany patent application no. DE 10 2007 011 485.2, filed Mar. 7, 2007, the entire disclosure of which is incorporated herein by reference. 
     BACKGROUND OF THE INVENTION 
     The present invention relates to a multiparticulate dosage form with impeded abuse containing, in addition to one or more active substances having abuse potential (A), optionally at least one physiologically acceptable auxiliary (B), at least one synthetic or natural polymer (C), optionally at least one wax (D) and at least one disintegrating agent (E), with the individual particles of the dosage form having a breaking strength of at least 500 N and a release of the active substance of at least 75% after 45 minutes, and relates to processes for the preparation of the dosage form according to the invention. 
     A large number of pharmaceutical active substances not only have an outstanding efficacy in their relevant field of application, but also a potential for being abused, i.e. an abuser can use them to produce effects which are not consistent with their intended use. Thus, for example opiates which exhibit an excellent efficacy in controlling severe to extremely severe pain, are frequently abused to induce euphoric states similar to being intoxicated. In particular, active substances which have a psychotropic effect are abused accordingly. 
     To enable abuse, the corresponding dosage forms, such as tablets or capsules are crushed, for example ground by the abuser, the active substance is extracted from the thus obtained powder using a preferably aqueous liquid and after being optionally filtered through cotton wool or cellulose wadding, the resultant solution is administered parenterally, in particular intravenously. This type of dosage results in an even faster diffusion of the active substance compared to the oral abuse, with the result desired by the abuser, namely the kick. This kick or these intoxication-like, euphoric states are also reached if the powdered dosage form is dosage nasally, i.e. is sniffed. 
     To prevent these possibilities of abuse, it is proposed in U.S. Pat. No. 4,070,494 to add an agent capable of swelling to the dosage form. This agent swells when water is added to extract the active substance which means that the filtrate separated from the gel contains only a very small amount of active substance. 
     A corresponding approach for preventing parenteral abuse is also the dosage form of a multi-layer tablet disclosed in U.S. Pat. No. 6,309,668 (=WO 95/20947) which has the active substance with a potential for abuse and at least one gel former respectively separated in different layers. 
     A further approach for preventing parenteral abuse is disclosed in U.S. Pat. No. 7,214,385 (=WO 03/015531). This document describes a dosage form containing an analgesic opioid and a dye as an aversive agent. The color, released by inadmissible manipulation of the dosage form, is supposed to prevent the abuser from using this manipulated dosage form. 
     Another known possibility for impeding abuse is to add to the dosage form antagonists of the active substance, for example naloxone or naltrexone in the case of opioids, or to add to the dosage form compounds which lead to physiological deterrent reactions, for example Radix Ipecacuanha=ipecac root. 
     It is also known to prevent abuse by complicating or preventing the pulverization, necessary for abuse, of the dosage forms by the means usually available to a potential abuser. US 2005/031546 (=DE 103 36 400) discloses appropriately solid dosage forms containing active substance with abuse potential which, when used as intended, ensure the desired therapeutic effect, but from which the active substances cannot be converted by simple pulverization into a form capable of being abused. 
     These dosage forms secured against abuse are distinguished by a controlled, preferably retarded release of the active substance which has abuse potential. However, a rapid release of the active substance is necessary for numerous therapeutic applications, for example pain relief using active substances with abuse potential. 
     SUMMARY OF THE INVENTION 
     It was therefore the object of the present invention to provide a dosage form containing an active substance with abuse potential, the abuse of which is at least impeded and which dosage form ensures a reproducible, rapid release of the active substance with abuse potential. 
     This object is achieved by providing the multiparticulate dosage form according to the invention with impeded abuse potential, comprising
         at least one active substance with abuse potential (A),   at least one synthetic or natural polymer (C),   optionally at least one synthetic, semi-synthetic or natural wax (D),   at least one disintegrating agent (E), and   optionally one or more other physiologically acceptable auxiliaries (B),
 
the individual particles of the dosage form having a breaking strength of at least 500 N and an active substance release of at least 75% after 45 minutes, measured according to Pharm. Eur. in a paddle mixer with sinker in 600 ml of aqueous buffer solution with a pH value of 1.2 at 37° C. and 75 rpm (revolutions per minute).
       

     By using polymers which have a minimum breaking strength of at least 500 N (measured as stated in the application) in quantities such that the particles of the dosage form according to the invention have a minimum breaking strength of at least 500 N it is possible to prevent pulverization of the dosage with usual means and thus prevent the subsequent abuse or to make it at least very difficult. 
     A parenteral, in particular an intravenous, safe application or an improper nasal application is impossible without an adequate comminution step, so that it is impossible to reach the intoxication-like, euphoric states achieved thereby in the desired intensity and with the desired rapidity. 
     According to the invention, the term comminution means the pulverization of the dosage form using conventional means usually available to an abuser, for example a pestle and mortar, a hammer, a mallet or other conventional means for pulverizing under the action of force. 
     The multiparticulate dosage forms according to the invention are therefore suitable for preventing the parenteral and/or nasal abuse of active substances, preferably pharmaceutical active substances, which have a potential for being misused and ensure a rapid, controlled release of the active substance due to their composition according to the invention. Therefore, they correspond to the so-called IR dosage forms (immediate release dosage forms), since the release profile of the active substance meets the corresponding standard conditions. The multiparticulate dosage forms most preferably exhibit a release of the active substances within 1 to 30 minutes. 
     Pharmaceutical active substances which have abuse potential are known to persons skilled in the art, as are the quantities thereof which are to be used and processes for the preparation thereof, and can be present as such in the dosage form according to the invention or, in the form of the corresponding derivatives thereof, in particular esters or ethers, or respectively in the form of corresponding physiologically acceptable compounds, in particular in the form of the corresponding salts or solvates thereof, as racemates or stereoisomers. The multiparticulate dosage form according to the invention is also suitable for the dosage of a plurality of pharmaceutical active substances in one dosage form. The dosage form preferably contains only one specific active ingredient with abuse potential. 
     The rapid release dosage form according to the invention is particularly suitable for impeding or preventing the abuse of at least one pharmaceutical active substance with abuse potential, selected from the group including opioids, tranquillisers, preferably benzodiazepine, barbiturates, stimulants and other narcotics, in particular active substances with a psychotropic effect. 
     The dosage form according to the invention is more particularly suitable for impeding or preventing the abuse of an opioid, a tranquillizer or another narcotic selected from the group consisting of N-{1-[2-(4-ethyl-5-oxo-2-tetrazolin-1-yl)ethyl]-4-methoxymethyl-4-piperidyl}propionanilide (alfentanil), 5,5-diallylbarbituric acid (allobarbital), allylprodine, alphaprodine, 8-chloro-1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]-benzodiazepine (alprazolam), 2-diethylaminopropiophenone (amfepramone), (±)-α-methylphenethylamine (amphetamine), 2-α-methylphenethylamino)-2-phenylacetonitrile (amphetaminil), 5-ethyl-5-isopentylbarbituric acid (amobarbital), anileridine, apocodeine, 5,5-diethylbarbituric acid (barbital), benzylmorphine, bezitramide, 7-bromo-5-(2-pyridyl)-1H-1,4-benzodiazepin-2(3H)-one (bromazepam), 2-bromo-4-(2-chlorophenyl)-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine (brotizolam), 17-cyclopropylmethyl-4,5α-epopxy-7α[(S)-1-hydroxy-1,2,2-trimethyl-propyl]-6-methoxy-6,14-endo-ethanomorphinan-3-ol (buprenorphine), 5-butyl-5-ethylbarbituric acid (butobarbital), butorphanol, (7-chloro-1,3-dihydro-1-methyl-2-oxo-5-phenyl-2H-1,4-benzodiazepin-3-yl)-dimethyl-carbamate (camazepam), (1S,2S)-2-amino-1-phenyl-1-propanol (cathine/D-norpseudoephedrine), 7-chloro-N-methyl-5-phenyl-3H-1,4-benzodiazepin-2-ylamine-4-oxide (chlorodiazepoxide), 7-chloro-1-methyl-5-phenyl-1H-1,5-benzodiazepine-2,4(3H,5H)-dione (clobazam), 5-(2-chlorophenyl)-7-nitro-1H-1,4-benzodiazepin-2(3H)-one (clonazepam), clonitazene, 7-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepine-3-carboxylic acid (clorazepate), 5-(2-chlorophenyl)-7-ethyl-1-methyl-1H-thieno[2,3-e][1,4]diazepin-2(3H)-one (clotiazepam), 10-chloro-11b-(2chlorophenyl)-2,3,7,11b-tetrahydrooxazolo[3,2-d][1,4]benzodiazepine-6(5H)-one (cloxazolam), (−)-methyl-[3μ-benzoyloxy-2β(1αH,5αH)-tropancarboxylate] (cocaine), 4,5α-epoxy-3-methoxy-17-methyl-7-morphinen-6α-ol (codeine), 5-(1-cyclohexenyl)-5-ethylbarbituric acid (cyclobarbital), cyclorphan, cyprenorphine, 7-chloro-5-(2-chlorophenyl)-1H-1,4-benzodiazepin-2(3H)-one (delorazepam), desomorphine, dextromoramide, (+)-(1-benzyl-3-dimethylamino-2-methyl-1-phenylpropyl)propionate (dextropropoxyphene), dezocine, diampromide, diamorphone, diamorphine (heroin), 7-chloro-1-methyl-5-phenyl-1H-1,4-benzodiazepin-2(3H)-one (diazepam), 4,5α-epoxy-3-methoxy-17-methyl-6α-morphinanol (dihydrocodeine), 4,5α-epoxy-17-methyl-3,6α-morphinandiol (dihydromorphine), dimenoxadol, dimephetamol, dimethylthiambutene, dioxaphetylbutyrate, dipipanone, (6aR,10aR)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol (dronabinol), eptazocine, 8-chloro-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine (estazolam), ethoheptazine, ethylmethylthiambutene, ethyl-[7-chloro-5-(2-fluorophenyl)-2,3-dihydro-2-oxo-1H-1,4 benzodiazepine-3-carboxylate] (ethylloflazepate), 4,5α-epoxy-3-ethoxy-17-methyl-7-morphinen-6α-ol (ethyl morphine), etonitazene, 4,5α-epoxy-7α-(1-hydroxy-1-methylbutyl)-6-methoxy-17-methyl-6,14-endo-etheno-morphinan-3-ol (etorphine), N-ethyl-3-phenyl-8,9,10-trinorbornan-2-ylamine (fencamfamine), 7-[2-(α-methylphenethylamino)ethyl]-theophylline) (fenetylline), 3-α-methylphenethylamino)propionitrile (fenproporex), N-(1-phenethyl-4-piperidyl)propionanilide (fentanyl), 7-chloro-5-(2-fluorophenyl)-1-methyl-1H-1,4-benzodiazepin-2(3H)-one (fludiazepam), 5-(2-fluorophenyl)-1-methyl-7-nitro-1H-1,4-benzodiazepin-2(3H)-one (flunitrazepam), 7-chloro-1-(2-diethylaminoethyl)-5-(2-fluorophenyl)-1H-1,4-benzodiazepin-2(3H)-one (flurazepam), 7-chloro-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-2(3H)-one (halazepam), 10-bromo-11b-(2-fluorophenyl)-2,3,7,11b-tetrahydro[1,3]oxazolo[3,2-d][1,4]benzodiazepin-6(5H)-one (haloxazolam), heroin, 4,5α-epoxy-3-methoxy-17-methyl-6-morphinanone (hydrocodone), 4,5α-epoxy-3-hydroxy-17-methyl-6-morphinanone (hydromorphone), hydroxypethidine, isomethadone, hydroxymethylmorphinane, 11-chloro-8,12b-dihydro-2,8-dimethyl-12b-phenyl-4H-[1,3]oxazino[3,2-d][1,4]benzodiazepin-4,7(6H)-dione (ketazolam), 1-[4-(3-hydroxyphenyl)-1-methyl-4-piperidyl]-1-propanone (ketobemidone), (3S,6S)-6-dimethylamino-4,4-diphenylheptan-3-ylacetate (levacetylmethadol (LAAM)), (−)-6-dimethylamino-4,4-diphenyl-3-heptanone (levomethadone), (−)-17-methyl-3-morphinanol (levorphanol), levophenacylmorphane, lofentanil, 6-(2-chlorophenyl)-2-(4-methyl-1-piperazinylmethylene)-8-nitro-2H-imidazo[1,2-a][1,4]benzodiazepin-1(4H)-one (loprazolam), 7-chloro-5-(2-chlorophenyl)-3-hydroxy-1H-1,4-benzodiazepin-2(3H)-one (lorazepam), 7-chloro-5-(2-chlorophenyl)-3-hydroxy-1-methyl-1H-1,4-benzodiazepin-2(3H)-one (lormetazepam), 5-(4-chlorophenyl)-2,5-dihydro-3H-imidazo[2,1-a]isoindol-5-ol (mazindol), 7-chloro-2,3-dihydro-1-methyl-5-phenyl-1H-1,4-benzodiazepine (medazepam), N-(3-chloropropyl)-α-methylphenethylamine (mefenorex), meperidine, 2-methyl-2-propyltrimethylenedicarbamate (meprobamate), meptazinol, metazocine, methylmorphine, N,α-dimethylphenethylamine (methamphetamine), (+)-6-dimethylamino-4,4-diphenyl-3-heptanone (methadone), 2-methyl-3-o-tolyl-4(3H)-quinazolinone (methaqualone), methyl-[2-phenyl-2-(2-piperidyl)acetate] (methylphenidate), 5-ethyl-1-methyl-5-phenylbarbituric acid (methylphenobarbital), 3,3-diethyl-5-methyl-2,4-piperidindione (methyprylon), metopon, 8-chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]benzodiazepine (midazolam), 2-(benzhydrylsulfinyl)acetamide (modafinil), 4,5α-epoxy-17-methyl-7-morphinene-3,6α-diol (morphine), myrophine, (±)-trans-3-(1,1-dimethylheptyl)-7,8,10,10α-tetrahydro-1-hydroxy-6,6-dimethyl-6H-dibenzo[b,d]pyran-9(6αH)-one (nabilone), nalbuphene, nalorphine, narceine, nicomorphine, 1-methyl-7-nitro-5-phenyl-1H-1,4-benzodiazepin-2(3H)-one (nimetazepam), 7-nitro-5-phenyl-1H-1,4-benzodiazepin-2(3H)-one (nitrazepam), 7-chloro-5-phenyl-1H-1,4-benzodiazepin-2(3H)-one (nordazepam), norlevorphanol, 6-dimethylamino-4,4-diphenyl-3-hexanone (normethadone), normorphine, norpipanone, the exudation of plants belonging to the species  Papaver somniferum  (opium), 7-chloro-3-hydroxy-5-phenyl-1H-1,4-benzodiazepine-2(3H)-one (oxazepam), (cis-trans)-10-chloro-2,3,7,11b-tetrahydro-2-methyl-11b-phenyloxazolo[3,2-d][1,4]benzodiazepin-6-(5H)-one (oxazolam), 4,5α-epoxy-14-hydroxy-3-methoxy-17-methyl-6-morphinanone (oxycodone), oxymorphone, plants and parts of plants belonging to the species  Papaver somniferum  (including the subspecies  setigerum ) ( Papaver somniferum ), papavereturn, 2-imino-5-phenyl-4-oxazolidinone (pernoline), 1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-2,6-methano-3-benzazocin-8-ol (pentazocine), 5-ethyl-5-(1-methylbutyl)-barbituric acid (pentobarbital), ethyl-(1-methyl-4-phenyl-4-piperidinecarboxylate) (pethidine), phenadoxone, phenomorphan, phenazocine, phenoperidine, piminodine, pholcodeine, 3-methyl-2-phenylmorpholine (phenmetrazine), 5-ethyl-5-phenylbarbituric acid (phenobarbital), α,α-dimethylphenethylamine (phentermine), 7-chloro-5-phenyl-1-(2-propinyl)-1H-1,4-benzodiazepin-2(3H)-one (pinazepam), α-(2-piperidyl)benzhydrylalcohol (pipradrol), 1′-(3-cyano-3,3-diphenylpropyl)[1,4′-bipiperidine]-4′-carboxamide (piritramide), 7-chloro-1-(cyclopropylmethyl)-5-phenyl-1H-1,4-benzodiazepin-2(3H)-one (prazepam), profadol, proheptazine, promedol, properidine, propoxyphene, pseudoephedrine, N-(1-methyl-2-piperidinoethyl)-N-(2-pyridyl)propionamide, methyl{3-[4-methoxycarbonyl-4-(N-phenylpropanamido)piperidino]propanoate} (remifentanile), 5-sec-butyl-5-ethylbarbituric acid (secbutabarbital), 5-allyl-5-(1-methylbutyl)-barbituric acid (secobarbital), N-{4-methoxymethyl-1-[2-(2-thienyl)ethyl]-4-piperidyl}propionanilide (sufentanil), 7-chloro-2-hydroxy-methyl-5-phenyl-1H-1,4-benzodiazepin-2(3H)-one (temazepam), 7-chloro-5-(1-cyclohexenyl)-1-methyl-1H-1,4-benzodiazepin-2(3H)-one (tetrazepam), ethyl-(2-dimethylamino-1-phenyl-3-cyclohexene-1-carboxylate) (tilidine (cis and trans)), tramadol, 8-chloro-6-(2-chlorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine (triazolam), 5-(1-methylbutyl)-5-vinylbarbituric acid (vinylbital), (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol, (1R,2R,4S)-2-[dimethylamino)methyl-4-(p-fluorobenzyloxy)-1-(m-methoxyphenyl)cyclohexanol, (1R,2R)-3-(2-dimethylaminomethyl-cyclohexyl)-phenol, (1S,2S)-3(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol, (2R,3R)-1-dimethylamino-3(3-methoxy-phenyl)-2-methyl-pentan-3-ol, (1RS,3RS,6RS)-6-dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol, preferably as racemate, 3-(2-dimethylaminomethyl-1-hydroxy-cyclohexyl)-phenyl 2-(4-isobutyl-phenyl)-propionate, 3-(2-dimethylaminomethyl-1-hydroxy-cyclohexyl)phenyl 2-(6-methoxy-naphthalen-2-yl)-xpropionate, 3-(2-dimethylaminomethyl-cyclohex-1-enyl)-phenyl 2-(4-isobutyl-phenyl)-propionate, 3-(2-dimethylaminomethyl-cyclohex-1-enyl)-phenyl 2-(6-methoxy-naphthalen-2-yl)-propionate, (RR—SS)-2-acetoxy-4-trifluoromethyl-benzoic acid 3-(2-dimethylaminomethyl-1-hydroxy-cyclohexyl)-phenyl ester, (RR—SS)-2-hydroxy-4-trifluoromethyl-benzoic acid 3-(2-dimethylaminomethyl-1-hydroxy-cyclohexyl)-phenyl ester, (RR—SS)-4-chloro-2-hydroxy-benzoic acid 3-(2-dimethylaminomethyl-1-hydroxy-cyclohexyl)-phenyl ester, (RR—SS)-2-hydroxy-4-methyl-benzoic acid 3-(2-dimethylaminomethyl-1-hydroxy-cyclohexyl)-phenyl ester, (RR—SS)-2-hydroxy-4-methoxy-benzoic acid 3-(2-dimethylaminomethyl-1-hydroxy-cyclohexyl)-phenyl-ester, (RR—SS)-2-hydroxy-5-nitro-benzoic acid 3-(2-dimethylaminomethyl-1-hydroxy-cyclohexyl)-phenyl ester, (RR—SS)-2′,4′-difluoro-3-hydroxy-biphenyl-4-carboxylic acid 3-(2-dimethylaminomethyl-1-hydroxy-cyclohexyl)-phenyl ester and corresponding stereoisomeric compounds, respectively the corresponding derivatives thereof, in particular amides, esters or ethers, and respectively the physiologically acceptable compounds thereof, in particular the salts and solvates thereof, more preferably hydrochlorides. 
     The dosage form according to the invention is particularly suitable for impeding or preventing the abuse of an opioid active ingredient selected from the group consisting of oxycodone, diamorphine, ethylmorphine, hydrocodone, oxymorphone, hydromorphone, morphine, tramadol and the physiologically acceptable derivatives thereof or compounds, preferably the salts and solvates thereof, preferably the hydrochlorides thereof, physiologically acceptable enantiomers, stereoisomers, diastereomers and racemates and the physiologically acceptable derivatives thereof, preferably ethers, esters or amides. 
     Furthermore, the dosage form according to the invention is particularly suitable for impeding or preventing the abuse of an opioid active substance selected from the group consisting of (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol, (2R,3R)-1-dimethylamino-3-(3-methoxy-phenyl)-2-methyl-pentan-3-ol, (1RS,3RS,6RS)-6-dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol, (1R,2R)-3-(2-dimethylaminonethyl-cyclohexyl)-phenol, the physiologically acceptable salts thereof, preferably hydrochlorides, phosphates, maleates, physiologically acceptable enantiomers, stereoisomers, diastereomers and racemates and the physiologically acceptable derivatives thereof, preferably ethers, esters or amides. 
     These compounds and respectively the preparation method thereof are described respectively in U.S. Pat. No. 6,248,737 (=EP 693,475) and U.S. Pat. No. 5,801,201 (=EP 780,369), the entire disclosures of which are incorporated herein by reference. 
     To achieve the requisite breaking strength of the particles of the dosage form according to the invention, at least one synthetic or natural polymer (C) is used which has a breaking strength, measured by the method disclosed in the present application, of at least 500 N. For this purpose, it is preferable to use at least one polymer selected from the group consisting of polyalkylene oxides, preferably polymethylene oxide, polyethylene oxide, polypropylene oxide; polyethylenes, polypropylenes, polyvinylchlorides, polycarbonates, polystyrenes, polyacrylates, the copolymers thereof and mixtures of at least two of the mentioned polymers. High-molecular-weight, thermoplastic polyalkylene oxides are particularly preferred. More preferred are high-molecular-weight polyethylene oxides having a molecular weight of at least 0.5 million, preferably of at least 1 million, more preferably 1 million to 15 million, most preferably from 1 to 10 million, determined by rheological measurements. These polymers have a viscosity at 25° C. of 4500 to 17600 cP, measured on a 5% by weight aqueous solution using a Brookfield viscosimeter, model RVF (spindle no. 2/rotation speed 2 rpm), of 400 to 4000 cP, measured on a 2% by weight aqueous solution using the mentioned viscosimeter (spindle no. 1 or 3/rotation speed 10 rpm) or a viscosity of 1650 to 10000 cP, measured on a 1% by weight aqueous solution using the mentioned viscosimeter (spindle no. 2/rotation speed 2 rpm). The polymers are preferably used as a powder. They can be soluble in water. 
     Furthermore, additionally to the polymer (C) to achieve the requisite breaking strength of the particles of the dosage form according to the invention, it is also possible to use at least one natural, semi-synthetic or synthetic wax (D) with a breaking strength, measured by the method disclosed in the present application, of at least 500 N. Waxes with a softening point of at least 50° C., more preferably 60° C. are preferred. Carnauba wax and beeswax are particularly preferred, especially carnauba wax. Carnauba wax is a natural wax which is obtained from the leaves of the carnauba palm and has a softening point of at least 80° C. When the wax component is additionally used, it is added together with at least one polymer (C) in quantities such that the particles of the dosage form have a breaking strength of at least 500 N. 
     Component (C) is preferably used in a quantity of from 35 to 99.9% by weight, more preferably in a quantity of at least 40% by weight and most preferably in a quantity of from 40 to 70% by weight, based on the total weight of the dosage form. 
     Physiologically acceptable disintegrats agents, such as are used for the preparation of pharmaceutical dosage forms can be used as disintegrats (E). Preferred for use as disintegrat (E) is at least one disintegrat selected from the group consisting of crosslinked sodium carboxymethyl cellulose (crosscamellose), modified maize starch, sodium carboxymethyl starch, crosslinked polyvinylpyrrolidone (crosspovidone). The dosage forms according to the invention preferably contain from 0.5 to 25% by weight, more preferably from 1 to 10% by weight, based on the total weight of the dosage form, of at least one disintegrating agent (E). 
     The disintegrat is preferably used in powder form and is present in the dosage form according to the invention in the particles and/or on the particles and/or distributed loosely alongside the particles. The disintegrating agent (E) is preferably at least partly in the form of a formulation component in the particles of the dosage form according to the invention and/or at least partly enveloping the particles, preferably in a coating on the particles and/or at least partly mixed with the particles of the dosage form. The disintegrat most preferably present as a formulation component in the particles and also as a component enveloping the particles. 
     The conventional auxiliaries (B1) which are preferably thermally stable and are known for the formulation of solid dosage forms can be used as further auxiliaries (B). These are preferably plasticizers, fillers, antioxidants and/or redox stabilizers. 
     Suitable antioxidants preferably include ascorbic acid, α-tocopherol, butylhydroxyanisol, butylhydroxytoluene, salts of ascorbic acid, ascorbylic palmitate, monothioglycerine, phosphoric acid, vitamin C, vitamin E and the derivatives thereof, such as vitamin E-succinate or vitamin E-palmitate and/or sodium bisulfite, more preferably butylhydroxytoluene (BHT) or butylhydroxyanisol (BHA) and/or α-tocopherol. 
     The antioxidant is preferably used in quantities of from 0.01 to 10% by weight, preferably from 0.03 to 5% by weight, based on the total weight of the dosage form. 
     Methylcellulose, hydroxyproplyl cellulose, hydroxyproplylmethyl cellulose, calcium dihydrogen phosphate and/or tricalcium phosphate can preferably also be used as fillers in the particles of the dosage form according to the invention. 
     Preferred plasticizers which may be used include polyalkylene glycols such as polyethylene glycol, fatty acids, fatty acid esters, waxes and/or microcrystalline waxes. The plasticizers are used preferably in a quantity of from 5 to 20% by weight, based on the total weight of the composition of the particles. 
     Preferably as redox stabilizers chelating agents like citric acid, EDTA (ethylenediaminetetra acetic acid), maleic acid and/or fumaric acid are used. 
     Fillers, taste improving additives and/or lubricants can also preferably be used as auxiliaries (B2), which preferably are not components of the particles. 
     Preferred fillers which may be used include microcrystalline cellulose, calciumdihydrogenphosphate, sugar like lactose, sugar alcohols like mannitol, hydroxyproplylmethyl cellulose, powder cellulose, collidone and/or polyvinylpyrrolidone. 
     As taste improving additives aroma additives, effervescent additives, sugar, sugar alcohols and/or sugar substitutes can be used preferably. 
     As lubricants talcum, silicon dioxide, stearic acid, fatty acid esters, sugar esters and/or magnesium stearate can be used. 
     The multiparticulate dosage forms according to the invention are characterized in that, due to their hardness, they cannot be pulverized by conventional crushing means available to an abuser, such as a pestle and mortar. This impedes or prevents a parenteral, in particular intravenous or nasal abuse. However, to prevent any possible abuse of the dosage forms according to the invention, in a preferred embodiment the dosage forms according to the invention can contain further abuse-impeding or abuse-preventing agents as auxiliaries (B3). 
     Thus, in addition to containing one or more active substance with abuse potential, at least one hardness-forming polymer (C), at least one disintegrat (E), optionally at least one wax (D), optionally other auxiliaries (B1, B2), the multiparticulate dosage forms according to the invention can also contain at least one of the following components (a)-(e) as auxiliaries (B3):
         (a) at least one substance which at least irritates the nasal cavity,   (b) at least one antagonist for each of the active substances which are present in the dosage form and have abuse potential,   (c) at least one emetic,   (d) at least one dye as an aversive agent,   (e) at least one bitter substance.
 
The components (a) to (e) are additionally each individually suitable for safeguarding the dosage form according to the invention against abuse. Thus, component (a) is preferably suitable for safeguarding against nasal and/or parenteral, preferably intravenous abuse, component (b) is preferably suitable for safeguarding against nasal and/or parenteral, more preferably intravenous abuse, component (c) is preferably suitable for safeguarding against parenteral, more preferably intravenous, and/or oral and/or nasal abuse, component (d) as a visual deterrent against oral or parenteral abuse and component (e) against oral or nasal abuse. The included use according to the invention of at least one of the aforementioned components makes it possible to impede abuse more effectively in the case of dosage forms according to the invention.
       

     In one embodiment, the dosage form according to the invention can also contain one or more of the components (a)-(e) in a combination, preferably (a) and optionally (c) and/or (e) and/or (d) or (a) and optionally (c) and/or (d) and/or (e). 
     In a further embodiment, the dosage form according to the invention can contain all the components (a)-(e). 
     If the dosage form according to the invention comprises component (a) against abuse, substances considered according to the invention as irritating the nasal cavities and/or the pharynx are all those which, upon appropriate application via the nasal cavities and/or the pharynx, produce a reaction which is either so unpleasant for the abuser that he no longer wishes, or is able, to continue the application, for example a burning sensation, or which counteracts in a physiological manner the absorption of the corresponding active substance, for example by an increased nasal secretion production or by sneezing. These substances which usually irritate the nasal cavities and/or the pharynx can cause a very unpleasant feeling culminating in unbearable pain during parenteral, in particular intravenous application as well, so that the abuser no longer wishes, or is able, to continue administration. 
     Particularly suitable substances which irritate the nasal cavities and/or the pharynx are those which cause a burning sensation, an itching, an urge to sneeze, an increased secretion production or a combination of at least two of these stimuli. Appropriate substances and the quantities thereof which are conventionally to be used are known per se to a person skilled in the art or can be determined by simple preliminary tests. 
     The substance irritating the nasal cavities and/or pharynx of component (a) is preferably based on one or more constituents or one or more plant parts of at least one hot substance drug. 
     Suitable pungent drugs are known per se to persons skilled in the art and are described, for example in “Pharmazeutische Biologie—Drogen und ihre Inhaltsstoffe” (pharmaceutical biology—drugs and their ingredients) by Prof. Dr. Hildebert Wagner, 2 nd  revised edition, Gustav Fischer Verlag, Stuttgart—New York, 1982, pages 82 ff, the disclosure of which is incorporated herein by reference. 
     A dosage unit of the multiparticulate dosage form according to the invention is understood as meaning a separate or separable dose, for example a capsule filling of the dosage form according to the invention. 
     It is possible to add to the dosage form according to the invention as component (a) preferably one or more constituents of at least one pungent drug selected from the group consisting of Allii sativi Bulbus, Asari Rhizoma c. Herba, Calami Rhizoma, Capsici Fructus (paprika), Capsici Fructus acer (cayenne pepper), Curcumae longae Rhizoma, Curcumae xanthorrhizae Rhizoma, Galangae Rhizoma, Myristicae Semen, Piperis nigri Fructus (pepper), Sinapis albae (Erucae) Semen, Sinapis nigri Semen, Zedoariae Rhizoma and Zingiberis Rhizoma, more preferably from the group consisting of Capsici Fructus (paprika), Capsici Fructus acer (cayenne pepper) and Piperis nigri Fructus (pepper). 
     The ingredients of the pungent drugs are preferably o-methoxy(methyl)-phenol compounds, acid amide compounds, mustard oils or sulfide compounds or compounds derived therefrom. 
     At least one ingredient of the pungent drugs is particularly preferably selected from the group consisting of myristicin, elemicin, isoeugenol, α-asaron, safrol, gingerols, xanthorrhizol, capsaicinoids, preferably capsaicin, capsaicin derivatives, such as N-vanillyl-9E-octadecenamide, dihydrocapsaicin, nordihydrocapsaicin, homocapsaicin, norcapsaicin, and nomorcapsaicin, piperine, preferably trans-piperine, glucosinolates, preferably based on non-volatile mustard oil, more preferably based on p-hydroxybenzyl mustard oil, methylmercapto mustard oil or methylsulfonyl mustard oil, and compounds derived from these ingredients. 
     The dosage form according to the invention can preferably contain the plant parts of the corresponding pungent drugs in a quantity of from 0.01 to 30% by weight, more preferably 0.1 to 0.5% by weight, in each case based on the total weight of a dosage unit or unit dose. If one or more ingredients of corresponding pungent drugs are used, they are used in a quantity of preferably 0.001 to 0.005% by weight, based on the total weight of the dosage unit or unit dose. 
     Furthermore, to prevent and safeguard against abuse, the dosage form according to the invention can contain the component (b), namely one or more antagonists for the active substance or the active substances with abuse potential, the quantity of antagonist preferably being spatially separated from the remaining ingredients of the dosage form according to the invention and not having any effect when used as intended. 
     Suitable antagonists for preventing misuse of the active substances are known per se to persons skilled in the art and can be present in the dosage form according to the invention as such or in the form of corresponding derivatives, in particular esters or ethers, or respectively in the form of corresponding physiologically acceptable compounds, in particular in the form of the salts or solvates thereof. 
     If the active substance present in the dosage form is an opioid, the antagonist which is used is preferably selected from the group consisting of naloxone, naltrexone, nalmefene, nalide, nalmexone, nalorphine or naluphine, in each case optionally in the form of a corresponding physiologically acceptable compound, in particular in the form of a base, a salt or solvate. The corresponding antagonists, where component (b) is provided, are preferably used in a quantity of ≧1 mg, more preferably in a quantity of from 3 to 100 mg, most preferably in a quantity of from 5 to 50 mg per dosage form, i.e. per unit dose. 
     If the dosage form according to the invention contains a stimulant as active substance, the antagonist is preferably a neuroleptic, preferably at least one compound selected from the group consisting of haloperidol, promethacine, fluphenazine, perphenazine, levomepromazine, thioridazine, perazine, chlorpromazine, chlorprothixine, zuclopentixol, flupentexol, prothipendyl, zotepin, benperidol, pipamperone, melperone and bromperidol. 
     The dosage form according to the invention preferably contains these antagonists in a conventional therapeutic dosage known to a person skilled in the art, more preferably in a quantity per unit dose which is double to three times the conventional dosage. 
     If the combination for preventing and safeguarding against abuse of the dosage form according to the invention comprises component (c), it can comprise at least one emetic which should preferably be in a spatially separated arrangement from the remaining components of the dosage form according to the invention and should not have any effect in the body when used as intended. 
     Suitable emetics for preventing abuse of an active ingredient are known per se to persons skilled in the art and can be present as such in the dosage form according to the invention, or in the form of corresponding derivatives, in particular esters or ethers, or respectively in the form of the respective corresponding physiologically acceptable compounds, in particular in the form of the salts or solvates thereof. 
     In the dosage form according to the invention, an emetic can be considered which is based on one or more constituents of Radix Ipecacuanhae (ipecac root), preferably based on the constituent emetine, as described, for example in “Pharmazeutische Biologie—Drogen und ihre Inhaltsstoffe” by Prof. Dr. Hildebert Wagner, 2 nd  revised edition, Gustav Fischer Verlag, Stuttgart, New York, 1982, which is hereby incorporated herein by reference. 
     The dosage form according to the invention can preferably contain as component (c) the emetic emetine, preferably in a quantity of ≧3 mg, more preferably ≧10 mg and most preferably in a quantity of ≧20 mg per dosage form, i.e. per unit dose. 
     Apomorphine can likewise be preferably used as an emetic in safeguarding, according to the invention, against abuse, preferably in a quantity of preferably ≧3 mg, more preferably ≧5 mg and most preferably ≧7 mg per unit dose. 
     If the dosage form according to the invention contains component (d) as a further auxiliary preventing abuse, by using a dye of this type, in particular during an attempt to extract the active substance for a parenteral, preferably intravenous application, an intensive coloring of a corresponding aqueous solution is produced, which can deter a potential abuser. This coloring can also prevent an oral abuse which usually starts with an aqueous extraction of the active ingredient. Suitable dyes and the quantities required for the necessary deterrent effect are disclosed in U.S. Pat. No. 7,214,385 (=WO 03/015531) the entire disclosure of which is incorporated herein by reference. 
     If the dosage form according to the invention contains component (e) as a further auxiliary preventing abuse, oral and/or nasal abuse is further prevented by this addition of at least one bitter substance due to the taste of the dosage form being impaired. 
     Suitable bitter substances as well as the effective quantities are mentioned in U.S. Pat. No. 7,141,250, the entire disclosure of which is incorporated herein by reference. Suitable bitter substances preferably include aromatic oils, preferably peppermint oil, eucalyptus oil, bitter almond oil, menthol, fruit aroma substances, preferably aroma substances of lemons, oranges, limes, grapefruit or mixtures thereof, and/or denatonium benzoate (Bitrex®). Denatonium benzoate is particularly preferred. 
     The solid dosage form according to the invention is suitable for oral administration. 
     The multiparticulate dosage form according to the invention can be prepared by various processes which will be described in detail in the following; the invention also relates to dosage forms which can be obtained according to one of these processes: 
     The process for the preparation of the dosage form according to the invention preferably comprises the following steps:
         (a) mixing the components (A), optionally (B), (C), optionally (D) and optionally at least partly (E);   (b) optionally pre-forming the mixture obtained from step (a), preferably under the effect of heat and/or force on the mixture obtained from (a), the supplied amount of heat preferably not being enough to heat component (C) to its softening point;   (c) hardening the mixture under the effect of heat and force, it being possible for the heat to be supplied during and/or before the effect of force and the supplied amount of heat being sufficient to heat component (C) at least to its softening point;   (d) dividing the hardened mixture;   (e) optionally forming into the dosage form; and   (f) optionally coating with a coating containing component (E) and/or mixing with component (E) and optionally additives (B2).       

     The heat can be supplied directly or by using ultrasound. The action of force and/or the forming procedure of the dosage form can be carried out, for example using suitable extruders, in particular using twin-screw extruders (double roller extruders) or planetary roller extruders. 
     The following process variants are particularly preferred: 
     Process Variant 1: 
     In this embodiment, the dosage form according to the invention is preferably prepared using an extruder, by mixing preferably components (A), optionally (B), (C), the optionally present component (D) and optionally component (E) at least a portion of which is also used and, optionally after being granulated, the resultant mixture is formed to produce the dosage form by being subjected to force while being previously or simultaneously exposed to heat. An extruder is used for this heating procedure and the effect of force to produce the dosage form. 
     The components (A), optionally (B), (C), and optionally (D) are mixed in a mixer known to a person skilled in the art. The mixer can be, for example a roller mixer, a shaking mixer, a shearing mixer or a compulsory mixer. The action of force is applied until the dosage form has reached a breaking hardness of at least 500 N. Granulation can be effected by moist granulation or by melt granulation in known granulators. 
     This variant for the preparation of the dosage form according to the invention is more preferably carried out such that:
         a) the components (A), optionally (B), (C), the optionally present component (D) and optionally at least a portion of (E) are mixed;   b) the resultant mixture is heated in the extruder at least to the softening point of component (C) and is extruded through the outlet opening of the extruder under the action of force; and   c) the extrudate, which is still plastic, is divided and is optionally formed into the multiparticulate dosage form and optionally mixed and/or enveloped with component (E).
 
The components can preferably also be mixed according to process step a) in the extruder.
       

     Prior to mixing with the further components, component (C) and the optionally present component (D) are preferably provided according to the invention with an antioxidant. This can be carried out by mixing the two components (C) and the antioxidant, preferably in that the antioxidant is dissolved or suspended in a volatile solvent and this solution or suspension is mixed homogeneously with component (C) and the optionally present component (D) and the solvent is removed by drying, preferably in an inert gas atmosphere. 
     The preferably molten mixture which has been heated in the extruder to at least the softening point of component (C) is extruded out of the extruder through a nozzle which has at least one orifice. To carry out the process according to the invention, it is necessary to use suitable extruders, preferably screw extruders (roller extruders), extruders provided with twin screws (rollers) being particularly preferred. The screws preferably have eccentric nozzles and the extruder is preferably equipped with a displacer cone. 
     Extrusion is preferably carried out such that the expansion of the extrudates as a result of extrusion is at the most 50%, i.e. for example when an extrusion nozzle is used which has 1 mm orifices, the extrudates have a maximum diameter of 1.5 mm. The strand expansion is more preferably at most of 40%, even more preferably at most 35%, most preferably at most 30% and in particular at most 25%. It has surprisingly been found that when the extruded material is subjected to an excessive mechanical stress in the extruder, the strand expands to a considerable extent, resulting in undesirable non-uniformity of properties, in particular in the mechanical properties of the extrudate. 
     The extruder preferably has at least two temperature zones, in which case in the first zone which adjoins a feed and optionally mixing zone, the mixture is heated at least to the softening point of component (C). 
     After being heated at least to the softening point of component (C), the molten mixture is transported by the screws, is further homogenized, compressed or compacted such that it has a minimum pressure of 5 bar, preferably at least 10 bar immediately before being discharged from the extruder nozzle, and is extruded through the nozzle as an extrudate or extrudates, depending on the number of nozzle orifices. The nozzle preferably has a plurality of orifices. The nozzle geometry or the geometry of the orifices can be freely chosen. Thus, the nozzle or the orifices can have a circular, oblong or oval cross section, the circular cross section preferably having a diameter of from 0.1 mm to 5 mm. The nozzle or orifices preferably has/have a circular cross section. The barrel of the extruder used according to the invention can be heated or cooled. The corresponding temperature adjustment, i.e. heating or cooling, is based on the mixture to be extruded at least one average temperature (product temperature) corresponding to the softening temperature of component (C) and not exceeding temperature at which the physiologically active substance (A) being processed can be damaged. The temperature of the mixture to be extruded is preferably set below 180° C., preferably below 150° C., but at least at the softening temperature of component (C). 
     After the molten mixture has been extruded and after the extrudates have optionally been cooled, the extrudates are preferably divided. This is preferably carried out by cutting the extrudates using a revolving or rotating knife, a water-jet cutters, wires, blades or by laser cutters. A pelletizing step preferably follows division of the extrudates. 
     The action of force in the extruder on the at least plasticized mixture is adjusted by controlling the rotational speed of the feed device in the extruder and by the geometry thereof and by the dimensioning of the outlet such that the necessary pressure builds up in the extruder preferably before the actual extruding of the plasticated mixture. Using simple preliminary tests it is possible to establish the necessary extrusion parameters required for a particular composition in order to produce a dosage form which has a breaking strength of at least 500 N. 
     An example of a suitable extruder is a twin screw extruder from the company Leistritz (Nürnberg) of type ZSE 18 HP 40D, preferably with screws which are equipped with eccentric screw ends. A heatable nozzle plate with 8 orifices each having a diameter of 1.0 mm can be used as the nozzle. The extrusion parameters can be set, for example at the following values: screw speed: 150 rpm; throughput: 2 kg/h; product temperature: 60° C. to 140° C., preferably 80° C. to 140° C., more preferably 100° C. to 140° C. and most preferably 110° C. to 140° C. with corresponding barrel temperature. 
     Process Variant 2: 
     In this process variant for the production of the dosage form according to the invention. Energy is supplied via ultrasound. 
     First, a homogeneous mixture is prepared from at least component (A), component (C), optionally component (D) and optionally a portion of component (E). Additional auxiliaries (B1), for example fillers, plasticizers, lubricants or colorants, can also be incorporated in this mixture. A low-molecular polyethylene glycol is preferably used as plasticizer. 
     Mixing can be carried out using conventional mixers. For example, roller mixers, which are also known as tumbler, drum or rotary mixers, container mixers, barrel mixers (drum hoop mixers or tumbling mixers) or shaking mixers, shearing mixers, positive mixers, plough-share mixers, planetary kneader mixers, Z-kneaders, sigma-kneaders, fluid mixers or intensive mixers are suitable as mixers. The choice of a suitable mixer depends among other things on the flowability and cohesive forces of the product. 
     The mixture then undergoes forming. Forming of the mixture is preferably carried out during or after sonication, e.g. exposure to ultrasound. During sonication it is especially preferable to have direct contact between the mixture and the sonotrode of the ultrasonic equipment. A frequency of 1 kHz to 2 MHz, preferably 15 to 40 kHz, should be maintained during sonication. Sonication should continue until softening of the polymer (C) is achieved. Preferably this is achieved within a few seconds, especially preferably within 0.1 to 5 seconds, preferably 0.5 to 3 seconds. 
     Before the forming operation is carried out, the mixing operation can be followed by granulation of the mixture, after which the resultant granules are formed, by sonication and the action of force, to the dosage form, such as tablets. 
     Granulation can be carried out in the machines and apparatus known by a person skilled in the art. If granulation is carried out as wet granulation, water or aqueous solutions, e.g. ethanol/water or isopropanol/water, can be used as the granulation fluid. 
     The mixture or the granules produced therefrom can preferably also be submitted, for further forming, to melt extrusion, in which the mixture is melted by sonication and the action of force and is then extruded through nozzles. The extrudates thus obtained are then comminuted by means of known devices to the desired length. The comminuted product thus obtained can also optionally be pelletized, in order to obtain the multiparticulate dosage form according to the invention with a minimum breaking strength of 500 N. The particles are preferably also provided with any remaining amount of disintegrant and optionally additives (B2), before they are filled to a unit dose, e.g. in capsules, or are compressed to a tablet. 
     When using ultrasound, suitable parameters for plastication are: frequency 20 kHz; amplitude 50%. Furthermore, a force of 250 N should be applied. The action of ultrasound and force by means of the sonotrode can take for example 0.5 s, with the action of ultrasound and force preferably taking place simultaneously. 
     Process Variant 3: 
     In this process variant for the production of the multiparticulate dosage form according to the invention, components (A), (C), optionally (D), optionally at least one part of the disintegrant (E) and any auxiliaries (B1) that are present, such as antioxidants and plasticizers, are processed by means of a planetary roller extruder to the dosage form according to the invention. 
     Planetary roller extruders are known and are described in detail inter alia in the Handbuch der Kunststoff-Extrusionstechnik [Handbook of plastics extrusion technology] I (1989) “Principles” in Chapter 1.2 “Classification of extruders” pages 4-6, which are hereby incorporated herein by reference. 
    
    
     
       BRIEF DESCRIPTION OF THE DRAWINGS 
       The use of a planetary roller extruder for the production of the dosage form according to the invention is explained below, referring to  FIGS. 1 and 2 . These explanations are only provided as examples and do not restrict the scope of the invention. 
         FIG. 1  shows a section through a planetary roller extruder; 
         FIG. 2  shows the mode of action of the planetary roller extruder; 
         FIG. 3  shows the measurement of the breaking strength of a tablet. 
     
    
    
     DETAILED DESCRIPTION 
       FIG. 1  shows a planetary roller extruder, which can preferably be used for the production of the dosage forms according to the invention. This extruder essentially comprises a shaft  1 , which, relative to the direction of feed of the mixture of the aforementioned components that is being extruded, is constituted first as feed screw  5  and thereafter as central spindle  3  of the planetary roller extruder. Around the central spindle  3  are arranged preferably three to seven planetary spindles  4 , which are in their turn surrounded by a barrel in the form of a housing 6. 
     In the planetary roller extruder, referring to  FIG. 1 , the extrusion of the composition being used for production of a dosage form according to the invention is preferably carried out as follows. As indicated by arrow  2 , the components to be extruded are fed through the metering unit  7  in the region of the feed screw  5  and are transported by the rotation (drive not shown) towards the central spindle  3 . A person skilled in the art will understand that mixing together of the starting materials (components) is possible in the region of the feed screw. However, it is also possible to premix the components of the dosage form and feed this mixture via the metering unit  7  in the region of the feed screw  5 . The mixture is transported in the feed section of the planetary roller extruder. By heating at least to the softening point of component (C), the mixture is melted and there, in the region of the central spindle, i.e. in the extrusion section, the molten mixture is transported by interaction of the central spindle  3  and of the planetary spindles  4 , further homogenized, compressed or compacted and extruded as extrudates through the nozzle orifices  8 . The nozzle geometry or the geometry of the orifices can be chosen freely. Thus, the orifices can have a circular, oblong or oval cross-section, and the circular cross-section preferably has a diameter of 0.1 mm to 5 mm. The orifices preferably have a circular cross-section. Both the barrel  6  of the planetary roller extruder that is used according to the invention and the central spindle can be heated or cooled. The corresponding temperature adjustment, i.e. heating or cooling, is based on the mixture to be extruded having at least an average temperature corresponding to the softening point of component (C) and not exceeding a temperature at which the substance (A) being processed can be damaged. Preferably the temperature of the mixture being extruded is below 180° C., preferably below 150° C., but is at least set to the softening point of component (C). The reference symbols used refer exclusively to  FIGS. 1 and 2 . 
     Extrusion of the molten mixture and optional cooling of the extrudates is followed by comminution of the extrudates (not shown in  FIG. 1 ). The comminution can preferably be carried out by cutting of the extrudates by means of revolving or rotating knives, water-jet cutters, wires, blades or by means of laser cutters. 
     Optionally after further cooling of the comminuted extrudates, which are now preferably in the form of disks, optionally forming to the final form of the dosage form is carried out, preferably by pelletizing, and again with the action of heat if necessary. 
     The comminuted extrudates, optionally further formed, are preferably provided with (the remainder of) disintegrant (E) and optionally additives Finished in this way, as well as being compressed to tablets, they can also be used, in multiparticulate form, such as pellets or beads, for filling capsules, sachets, stick packs, in order to use the dosage form according to the invention as unit dose. 
       FIG. 2  shows a cross-section through the planetary roller extruder. Around the rotating central spindle  3 , at least three, in the illustrated case shown  6 , planetary spindles  4  are arranged, whose flanks  41  interact on the one hand with the flanks  31  of the central spindle  4  and on the other hand with the flanks  61  of the barrel  6  of the planetary roller extruder. Through the rotation of the central spindle  3  and the rolling of the respective flanks on one another, the planetary spindles  4  each rotate as shown by arrow  42  about their own axis and, as shown by arrow  43 , about the central spindle  4 . This leads to the desired compression or compacting of the mixture of components used according to the invention for the dosage forms produced according to the invention. The reference symbols used refer exclusively to  FIGS. 1 and 2 . 
     If necessary, the planetary roller extruder used can have not only an extrusion section, but also at least one other section, so that if required the mixture being extruded can also be degassed. The method can be carried out as a batch process or continuously, preferably continuously. A planetary roller extruder with four planetary spindles of type BCG 10 from the company LBB Bohle (Ennigerloh, Germany) with an extrusion nozzle with a diameter of 8 mm is, for example, suitable as the extruder. Gravity feed of 3.0 kg per hour is suitable. Extrusion can, for example, be carried out with a rotary speed of 28.6 rpm at a product temperature of approx. 88° C. 
     Process Variant 4: 
     In order to carry out this variant for the production of the dosage form according to the invention, at least the components (A), (C), optionally (D), optionally at least one part of the disintegrant (E) and any auxiliaries (B1) that are present, such as antioxidants and/or plasticizers, with addition of a solvent for component (C), i.e. for the polymer or polymers (C), are processed to the multiparticulate dosage form. 
     For this purpose, the components (A), optionally (B1), (C), component (D) if present and optionally at least one part of the disintegrant (E) are mixed together and the resultant formulation mixture, after addition of the solvent, is comminuted and optionally formed further. 
     The mixing of the components can be effected using mixers known to persons skilled in the art. The mixer can for example be a roller mixer, shaking mixer, shearing mixer or positive mixer. 
     The solvent for polymer (C) is added at least in amounts such that the formulation mixture is moistened uniformly. Preferably aqueous solvents, such as water, mixtures of water and aliphatic alcohols, preferably C 1 -C 6  alcohols, esters, ethers, hydrocarbons, and especially preferably distilled water, short-chain alcohols, such as methanol, ethanol, isopropanol, butanol or aqueous alcoholic solutions, are suitable as the solvent for polymer (C). The solvent is preferably added while stirring. Then the uniformly moistened mass is dried, preferably after comminution. Drying is preferably carried out under the action of heat, at temperatures at which discoloration of the mass can be ruled out. This temperature can be determined by simple preliminary tests. 
     It is also possible in order to moisten the formulation mixture as follows: Before adding the solvent, the formulation mixture, preferably divided into part masses in forms, is dispersed in a liquid dispersant with stirring, and then the solvent is added. Component (C) is not soluble in the dispersant, which must be miscible with the solvent. Preferably hydrophilic solvents, such as aliphatic alcohols, ketones, and esters, are suitable as the dispersant. Short-chain alcohols are preferably used. 
     Alternatively, moistening of the formulation mixture can also be carried out by incorporating the solvent as foam in the formulation mixture. Preferably said solvent foam is produced using high-speed mixers, preferably with addition of usual foam stabilizers. Hydrophilic polymers, e.g. hydroxypropyl methylcellulose, are suitable for example as stabilizers. Preferably the foam is also incorporated in the formulation mixture with stirring, by which preferably a granulated mass is obtained. 
     The granulated mass is dried and is then formed to the multiparticulate dosage form, e.g. by pelletizing. Drying and forming can preferably be carried out as stated above. The method according to the invention can also be carried out by adding sufficient solvent to the formulation mixture to produce a formable paste. 
     The paste can be divided into partial masses before or after drying, which can be carried out as described above. The partial masses can be formed as strands, which can be produced by a sieve or an extruder. The dried strands are preferably comminuted and finally formed to the dosage form, e.g. by pelletizing. It is also possible to process the paste to a flat shape, and then stamp the dosage form from the dried shape. Advantageously, the paste is processed using an extruder, in which, depending on the form of extrusion, the strands or flat shapes are produced, and are comminuted by fragmenting or cutting or stamping. The comminuted partial masses can be formed or stamped as described above to the dosage form. Appropriate apparatus for this is known to persons skilled in the art. 
     In any case the finally formed, multiparticulate dosage forms are optionally further provided with the (remaining) amount of component (E) and optionally with additives (B2), before being filled or compressed as a unit dose. The method of solution according to the invention can be carried out as a continuous process or as a batch process. 
     It is also possible to add sufficient solvent to the formulation mixture so that at least the polymeric component (C) is dissolved. Said solution or dispersion/suspension is preferably processed to a flat shape, preferably using an extruder with a flat nozzle or pouring the solution onto a flat, smooth substrate. 
     After drying, as stated above, the multiparticulate dosage forms can be obtained from the flat shapes by stamping or calendering. It is also possible to process the solution, as stated above, to produce strands, which are then, preferably after drying, comminuted and formed to the dosage form. 
     Alternatively, the solution can also be divided into partial amounts such that, after drying, in each case they correspond to the mass of a unit of the dosage form, preferably already using forms corresponding to the shape of a unit of the dosage form. If the solution is divided into arbitrary partial amounts, the partial amounts can, after drying, optionally be combined again to a unit dose, which can for example be filled in a capsule or compressed to a tablet. 
     Preferably the formulation mixtures to which solvent has been added are processed at temperatures from 20° C. to 40° C., and apart from drying to remove the solvent and the dispersant that is optionally present, no higher temperatures are employed. The temperature for drying must be selected below the decomposition temperature of the components. Optionally, after forming to the dosage form, drying corresponding to that described above can also take place. 
     Combinations of individual process steps of the aforementioned variants of the method are also possible, for producing the dosage form according to the invention. 
     The multiparticulate dosage forms according to the invention are preferably provided with a coating of disintegrant (E), to provide IR-release of the active substance. It is at least advantageous to mix the particles, preferably pellets, of the dosage form according to the invention with a disintegrant (E) and to dilute the mixture preferably with additional filler (B2), such as microcrystalline cellulose, magnesium stearate, calcium dihydrogen phosphate, lactose, fatty acid esters, mannitol, hydroxypropyl methylcellulose, pulverized cellulose, talc, silica, collidon, sugar esters and/or polyvinyl pyrrolidone. Said mixtures can be filled as unit dose in capsules, sachets or stick packs or can be processed to chewable tablets, dispersible tablets or IR-tablets. Quite especially preferably, the particles or pellets of the dosage form according to the invention have a coating comprising at least one disintegrant (E), which was applied by powder coating or film coating. The stated unit doses can, depending on the intended use, additionally contain aromatic substances, effervescent additives, sugars, sweeteners and/or dyes. 
     If the dosage form according to the invention contains component (c) and/or (e), the dosage is to be selected so that with oral application as directed, no negative action is produced. If, however, the intended dosage is exceeded during misuse, this produces nausea or retching or a bad taste. The particular amount of component (c) and/or (e), that is still tolerated by the patient with oral application as directed, can be determined by a person skilled in the art by simple preliminary tests. 
     If, however, independently of the practically impossible pulverizability of the dosage form according to the invention for safeguarding the dosage form, the use of components (b) and/or (c) and/or (e) is envisaged, these components should preferably be used at such a high dosage that with misuse of the dosage form they cause an intensive negative action in the abuser. This is preferably achieved by spatial separation at least of the active substance or active substances from components (b) and/or (c) and/or (e), preferably with the active substance or active substances being present in at least one subunit (X) and the components (b) and/or (c) and/or (e) in at least one subunit (Y), and with the components (b), (e) with application of the dosage form as directed, they do not produce their action on ingestion and/or in the body and the other components of the formulation, in particular component (C) and optionally (D) and (E), are identical. 
     If the dosage form according to the invention has at least 2 of the components (b) and (c) or (e), these can in each case be contained in the same or in different subunits (Y). Preferably, if they are present, all components (b), (c) and (e) are contained in one and the same subunit (Y). 
     Subunits in the sense of the present invention are solid formulations, which in each case contain, apart from the usual excipients known by a person skilled in the art, the active substance(s), at least one polymer (C) and at least one disintegrant (E), component (D) if present and optionally at least one of the optionally present components (a) and/or (e) or in each case at least one polymer (C) and optionally (D) and at least one disintegrant (E) and the antagonist(s) and/or the emetic(s) and/or component (d) and/or component (e) and optionally at least one of the optionally present components (a). It should be noted that each of the stated subunits is formulated according to the method stated above. 
     A substantial advantage of separate formulation of the active substances from components (b) or (c) or (e) in subunits (X) and (Y) of the dosage form according to the invention is that with application as directed, components (b) and/or (c) and/or (e) are practically not released on ingestion and/or in the body, or are only released in such small amounts that they have no adverse effect on the patient or on the success of treatment, or on passage through the patient&#39;s body they are only released at locations where absorption is insufficient for them to have an effect. Preferably, with application of the dosage form as directed, components (b) and/or (c) and/or (e) are practically not released in the patient&#39;s body or are not noticed by the patient. 
     A person skilled in the art will understand that the aforesaid conditions can vary depending on the components (b), (c) and/or (e) used in each case and the formulation of the subunits or of the dosage form. The optimum formulation for a particular dosage form can be determined by simple preliminary tests. What is decisive is that the respective subunits contain the polymer (C), the disintegrant (E) and optionally the component (D) and were formulated in the manner presented above. 
     If, contrary to expectations, abusers succeed in comminuting said dosage form according to the invention, which has components (b), (c) and/or (e) in subunits (Y), for the purpose of abusive ingestion of the active substance, and in obtaining a powder that is extracted with a suitable extractant, then apart from the active substance, also the respective component (b), (c) and/or (e) is obtained in a form in which it cannot be separated easily from the active substance, so that on application of the manipulated dosage form, in particular with oral and/or parenteral administration, it exerts its action on ingestion and/or in the body and additionally one of the components (b) and/or (c) and/or (e) produces a corresponding negative action in the abuser or deters an attempt to extract the active substance because of the coloration and so prevents abuse of the dosage form. 
     The formulation of a dosage form according to the invention, in which spatial separation of the active substance or active substances from components (b), (c) and/or (e) is preferably effected by formulation in different subunits, can be carried out in a variety of ways, and the corresponding subunits in the dosage form according to the invention can in each case be in any spatial arrangement relative to one another, provided the aforesaid conditions for the release of components (b) and/or (c) and/or (e) are fulfilled. 
     A person skilled in the art will understand that the component(s) (a) that are also optionally present preferably both in the respective subunits (X) and (Y) and in the form of independent subunits corresponding to subunits (X) and (Y) can be formulated in the dosage form according to the invention, provided that protection of the dosage form against abuse as well as the release of active substance with application as directed are not adversely affected by the manner of formulation and polymer (C), the disintegrant (E) and optionally (D) are included in the formulation and formulation is carried out according to the methods stated above to achieve the necessary hardness. 
     In a preferred embodiment of the dosage form according to the invention, the two subunits (X) and (Y) are in multiparticulate form, with microtablets, granules, spheroids, beads or pellets being preferred, and the same form, i.e. shape is selected both for subunit (X) and for subunit (Y), so that separation of the subunits (X) from (Y), e.g. by mechanical sorting, is not possible. The multiparticulate forms preferably have a size in the range from 0.1 to 5 mm, preferably 0.2 to 3 mm. 
     The dosage form according to the invention is in multiparticulate form, preferably in the form of microtablets, granules, spheroids, beads or pellets, optionally filled as a unit dose in capsules or compressed to form tablets, for oral administration. Preferably the multiparticulate forms have a size in the range from 0.1 to 5 mm, especially preferably in the range from 0.2 to 3 mm (method of determination according to published dissertation “Systematic investigations of the suitability of kappa-carrageenan as pelletizing excipient in wet extrusion/spheroidization, pages 16, 21-23 by Markus Thommes in the “Deutsche Bibliothek” in the German National Bibliography, 1st edition Cuvillin Verlag, Göttingen, 2006). 
     The subunits (X) and (Y) in multiparticulate form can also preferably be filled in a capsule, sachets, stick packs or compressed to a tablet, with the subunits (X) and (Y) also being retained in the resultant unit doses. 
     The respective multiparticulate subunits (X) or (Y) with identical forming should also not be distinguishable from one another visually, so that they cannot be separated from one another by the abuser by simple sorting. 
     Preferably, release of components (b), (c) and/or (e) from subunit (Y) of the dosage form according to the invention is prevented by a coating, so that the subunit can consist of usual materials known by a person skilled in the art, provided it contains at least one polymer (C), and optionally (D) to fulfil the hardness condition of the dosage form according to the invention and is provided with disintegrant (E). 
     The materials listed below can preferably be used for coating. Examples of preferred materials include those selected from the group consisting of alkyl celluloses, hydroxyalkyl celluloses, glucans, scleroglucans, mannans, xanthans, copolymers of poly[bis(p-carboxyphenoxy)propane and sebacic acid, preferably at a molar ratio of 20:80 (marketed under the designation Polifeprosan 20®), carboxymethyl celluloses, cellulose ethers, cellulose esters, nitrocelluloses, polymers based on (meth)acrylic acid and esters thereof, polyamides, polycarbonates, polyalkylenes, polyalkylene glycols, polyalkylene oxides, polyalkylene terephthalates, polyvinyl alcohols, polyvinyl ethers, polyvinyl esters, halogenated polyvinyls, polyglycolides, polysiloxanes, polyurethanes, their copolymers and their mixtures. 
     Especially suitable materials can be selected from the group consisting of methylcellulose, ethylcellulose, hydroxypropylcellulose, hydroxypropyl methylcellulose, hydroxybutyl methylcellulose, cellulose acetate, cellulose propionate (of low, medium or increased molecular weight), cellulose acetate-propionate, cellulose acetate-butyrate, cellulose acetate-phthalate, carboxymethylcellulose, cellulose triacetate, sodium-cellulose sulfate, polymethylmethacrylate, polyethylmethacrylate, polybutylmethacrylate, polyisobutylmethacrylate, polyhexylmethacrylate, polyisodecylmethacrylate, polylaurylmethacrylate, polyphenylmethacrylate, polymethylacrylate, polyisopropylacrylate, polyisobutylacrylate, polyoctate-decylacrylate, polyethylene, low-density polyethylene, high-density polyethylene, polypropylene, polyethylene glycol, polyethylene oxide, polyethylene terephthalate, polyvinyl alcohol, polyvinyl isobutyl ether, polyvinyl acetate and polyvinyl chloride. 
     Especially suitable copolymers can be selected from the group consisting of copolymers of butylmethacrylate and isobutylmethacrylate, copolymers of methylvinylether and maleic acid with high molecular weight, copolymers of methylvinylether and maleic acid monoethyl ester, copolymers of methylvinylether and maleic acid anhydride and copolymers of vinyl alcohol and vinyl acetate. 
     Other materials especially suitable for formulation of a coating are starch-filled polycaprolactone, see U.S. Pat. No. 7,176,251 (=WO 98/20073), aliphatic polyester amides, see U.S. Pat. No. 6,344,535 (=DE 19 753 534), CA 2,317,747 (=DE 19 800 698), U.S. Pat. No. 5,928,739 (=EP 820,698), aliphatic and aromatic polyester urethanes, see U.S. Pat. No. 6,821,588 (=DE 198 22 979), polyhydroxyalkanoates, in particular polyhydroxybutyrates, polyhydroxyvalerates), casein, see U.S. Pat. No. 5,681,517 (=DE 4 309 528), polylactides and copolylactides, see U.S. Pat. No. 6,235,825 (=EP 980,894). Each of the foregoing patent documents is hereby incorporated herein by reference in its entirety. 
     Optionally, the materials stated above can be mixed with other usual auxiliaries known by a person skilled in the art, preferably selected from the group consisting of plasticizers, lubricants, antioxidants, e.g. glycerol monostearate, semi-synthetic triglyceride derivatives, semi-synthetic glycerides, hydrogenated castor oil, glycerol palmitostearate, glycerol behenate, polyvinyl pyrrolidone, gelatin, magnesium stearate, stearic acid, sodium stearate, talc, sodium benzoate, boric acid and colloidal silica, fatty acids, substituted triglycerides, glycerides, polyoxyalkylene glycols, polyalkylene glycols and derivatives thereof. 
     The dosage form according to the invention displays IR-release, as defined above, of the active substance. It is therefore suitable preferably for treatment that is to have a quick effect, e.g. for control of acute pain. 
     Method of Determining the Breaking Strength 
     To verify whether a material can be used as component (C) or (D), the material is compressed to form a tablet with a diameter of 10 mm and a height of 5 mm with a force of 150 N, at a temperature corresponding at least to the softening point of the material and determined by means of a DSC diagram of the material. Tablets thus prepared are used for determining the breaking strength according to the method of determination of the breaking strength of tablets, published in the European Pharmacopoeia 1997, pages 143, 144, method No. 2.9.8., using the apparatus described below. The equipment used for the measurement is a Zwick material tester “Zwick Z 2.5”, material tester Fmax 2.5 kN with a traverse of max. 1150 mm, which is to be adjusted by setting up by means of a column and a spindle, a rear clearance of 100 mm and a testing speed adjustable from 0.1 to 800 mm/min and testControl software. A plunger die with screwable inserts and a cylinder (diameter 10 mm), a force transducer, Fmax. 1 kN, diameter 8 mm, class 0.5 from 10 N, class 1 from 2 N according to ISO 7500-1, with manufacturer&#39;s test certificate M according to DIN 55350-18 (Zwick-Bruttokraft Fmax 1.45 kN) are used for the measurement (all equipment from the company Zwick GmbH &amp; Co. KG, Ulm, Germany) with Order No. BTC-FR 2.5 TH. D09 for the tester, Order No. BTC-LC 0050N. P01 for the force transducer, Order No. BO 70000 S06 for the centring device. 
       FIG. 3  shows the measurement of the breaking strength of a tablet, in particular the adjuster ( 6 ) of the tablet ( 4 ) used before and during the measurement. For this, the tablet ( 4 ) is clamped between the upper pressure plate ( 1 ) and the lower pressure plate ( 3 ) of the device (not shown) for application of the force, by means of two 2-part clamping devices, which in each case are firmly secured (not shown) with the upper or lower pressure plate after setting the necessary distance ( 5 ) for receiving and for centring the tablet that is to be measured. For adjusting the distance ( 5 ), the 2-part clamping devices can in each case be moved horizontally outwards or inwards on the pressure plate carrying them. 
     Tablets for which no breakage was found, but possibly plastic deformation of the tablet without fracture occurred under the action of force, are also classed as breakage-resistant under the action of a defined force. 
     With the dosage forms obtained according to the invention, the breaking strength is determined by the method of measurement described, and the particles of the multiparticulate dosage forms other than tablets are also tested. 
     The invention will be explained in further detail hereinafter with reference to illustrative examples. These explanations are only provided as examples and do not limit the general scope of the invention. 
     EXAMPLES 
     Tramadol hydrochloride was used as the active substance in a number of examples. Tramadol hydrochloride was used, although tramadol is not an active substance with usual potential for misuse and therefore is not covered by the Narcotics Law, in order to facilitate the experimental work. Moreover, tramadol is a representative of the opioids class with excellent solubility in water. 
     Example 1 
     Pellet Production 
     Composition of the Pellets: 
     
       
         
               
               
             
               
               
               
               
             
           
               
                   
                   
               
               
                   
                 Proportion [%] 
               
               
                   
                   
               
             
             
               
                   
               
             
          
           
               
                 Tramadol HCl 
                 50 
                 mg 
                 40% 
               
               
                 Polyethylene oxide, NF 
                 50 
                 mg 
                 40% 
               
               
                 7 000 000 (MW) 
               
               
                 (Polyox WSR 303, Dow Chemicals) 
               
               
                 (Metholose 90 SH, 100000 cP) 
                 12.5 
                 mg 
                 10% 
               
               
                 hydroxypropyl methylcellulose 
               
               
                 (Shin-Etsu) 
               
               
                 PEG 6000 (polyethylene glycol) 
                 12.5 
                 mg 
                 10% 
               
               
                   
               
             
          
         
       
     
     The components were weighed and then mixed in a tumbler for 15 minutes. Then they were extruded using a twin-screw extruder from the company Leistritz, type ZSE18HP40D with micropelletizer. Eccentric screw tips and a displacer cone were used. The nozzle plate had eight orifices with a diameter of 1.0 mm and the length/diameter ratio was 2.5. The resultant pellets had a length of 1 mm±20%. The process parameters were as follows: 
     
       
         
               
               
               
             
           
               
                   
               
             
             
               
                   
                 Barrel temperature HZ1 required 40° C./actual: 
                 39.6° C.  
               
               
                   
                 Barrel temperature HZ2 and HZ2 
                 100° C. 
               
               
                   
                 Barrel temperature HZ4 to HZ8 
                 120° C. 
               
               
                   
                 Barrel temperature HZ10 
                 120° C. 
               
               
                   
                 Barrel temperature HZ11 
                 140° C. 
               
               
                   
                 Product temperature at discharge end 
                 134.1° C.   
               
               
                   
                 Discharge rate 
                 33.43 g/min 
               
               
                   
                 Screw speed (1/min) 
                 150/min 
               
               
                   
               
             
          
         
       
     
     The breaking strength of the pellets was determined by the method described above with the apparatus shown in  FIG. 3 . Fracture did not occur under the action of a force of 500 N. The pellets could not be crushed with a hammer, nor using pestle and mortar. 
     1.1. Capsule Production 
     Composition of the Capsule Filling 
     
       
         
               
               
               
               
               
             
           
               
                   
               
             
             
               
                   
                 Pellets produced according 
                 125 
                 mg 
                  95% 
               
               
                   
                 to Example 1.1. 
                   
                   
                   
               
               
                   
                 (≅50 mg tramadol) 
                   
                   
                   
               
               
                   
                 Crospovidone 
                 6.3 
                 mg 
                  5% 
               
               
                   
                 Total amount 
                 131.3 
                 mg 
                 100% 
               
               
                   
               
             
          
         
       
     
     The pellets produced according to 1.1. were mixed with crospovidone until a homogeneous mixture was obtained. Gelatin two-piece capsules of size 0 were filled with this mixture. 
     The in-vitro release of tramadol from the capsule was determined according to Ph.Eur. in a paddle stirrer with sinker. The temperature of the release medium was 37° C. and the rotary speed of the stirrer was 75 min −1 . 600 ml of buffer pH 1.2 was used as the release medium. The amount of tramadol released in each case in the dissolution medium at a specified time was determined by spectrophotometry (at 271 nm). 
     
       
         
               
               
               
             
           
               
                   
               
               
                   
                 Time 
                 Amount of active substance released 
               
               
                   
               
             
             
               
                   
                 15 min 
                 56% 
               
               
                   
                 30 min 
                 80% 
               
               
                   
                 45 min 
                 89% 
               
               
                   
               
             
          
         
       
     
     Example 2 
     2.1. Pellets Produced According to Example 1.1. Are Used 
     2.2. Composition of the Capsule Filling 
     
       
         
               
               
               
               
               
             
           
               
                   
               
             
             
               
                   
                 Pellets produced according 
                 125 
                 mg 
                  95% 
               
               
                   
                 to example 1.1. 
                   
                   
                   
               
               
                   
                 (≅50 mg tramadol) 
                   
                   
                   
               
               
                   
                 Croscarmellose 
                 6.3 
                 mg 
                  5% 
               
               
                   
                 Total amount 
                 131.3 
                 mg 
                 100% 
               
               
                   
               
             
          
         
       
     
     The pellets were mixed with croscarmellose and filled in gelatin two-piece capsules of size 0. The in-vitro release of tramadol from the capsule was determined according to Ph.Eur. in a paddle stirrer with sinker. The temperature of the release medium was 37° C. and the rotary speed of the stirrer was 75 min −1 . 600 ml of buffer pH 1.2 was used as the release medium. The amount of active substance released in each case in the dissolution medium at a specified time was determined by spectrophotometry (at 271 nm). 
     
       
         
               
               
               
             
           
               
                   
               
               
                   
                 Time 
                 Amount of active substance released 
               
               
                   
               
             
             
               
                   
                 15 min 
                 44% 
               
               
                   
                 30 min 
                 71% 
               
               
                   
                 45 min 
                 82% 
               
               
                   
               
             
          
         
       
     
     Example 3 
     3.1. Pellets Produced According to Example 1.1. Are Used 
     3.2. Composition of the Capsule Filling 
     
       
         
               
               
               
               
               
             
           
               
                   
               
             
             
               
                   
                 Pellets produced according 
                 125 
                 mg 
                 73.8% 
               
               
                   
                 to Example 1.1. 
                   
                   
                   
               
               
                   
                 (≅50 mg tramadol) 
                   
                   
                   
               
               
                   
                 Crospovidone 
                 6.3 
                 mg 
                  3.7% 
               
               
                   
                 Microcrystalline cellulose 
                 37.5 
                 mg 
                 22.1% 
               
               
                   
                 (Avicel PH101) 
                   
                   
                   
               
               
                   
                 Magnesium stearate 
                 0.6 
                 mg 
                  0.4% 
               
               
                   
                 Total amount 
                 169.4 
                 mg 
                  100% 
               
               
                   
               
             
          
         
       
     
     The pellets were mixed with croscarmellose, microcrystalline cellulose and magnesium stearate and filled in gelatin two-piece capsules of size 0. The in-vitro release of tramadol from the capsule was determined according to Ph.Eur. in a paddle stirrer with sinker. The temperature of the release medium was 37° C. and the rotary speed of the stirrer was 75 min − . 600 ml of buffer pH 1.2 was used as the release medium. The amount of active substance released in each case in the dissolution medium at a specified time was determined by spectrophotometry (at 271 nm). 
     
       
         
               
               
               
             
           
               
                   
               
               
                   
                 Time 
                 Amount of active substance released 
               
               
                   
               
             
             
               
                   
                 15 min 
                 70% 
               
               
                   
                 30 min 
                 88% 
               
               
                   
                 45 min 
                 92% 
               
               
                   
               
             
          
         
       
     
     Example 4 
     4.1. Pellets Produced According to Example 1.1. Were Used 
     4.2. Composition of the Capsule Filling 
     
       
         
               
               
               
               
               
             
           
               
                   
               
             
             
               
                   
                 Pellets produced according 
                 125 
                 mg 
                 66.7% 
               
               
                   
                 to Example 1.1. 
                   
                   
                   
               
               
                   
                 (≅50 mg tramadol) 
                   
                   
                   
               
               
                   
                 Croscarmellose 
                 6.25 
                 mg 
                  3.3% 
               
               
                   
                 Microcrystalline cellulose 
                 50.0 
                 mg 
                 26.7% 
               
               
                   
                 (Avicel PH101) 
                   
                   
                   
               
               
                   
                 Calcium dihydrogen phosphate 
                 6.25 
                 mg 
                  3.3% 
               
               
                   
                 Total amount 
                 187.5 
                 mg 
                  100% 
               
               
                   
               
             
          
         
       
     
     The pellets were mixed with the excipients and filled in gelatin two-piece capsules of size 0. The in-vitro release of tramadol from the capsule was determined according to Ph.Eur. in a paddle stirrer with sinker. The temperature of the release medium was 37° C. and the rotary speed of the stirrer was 75 min − . 600 ml of buffer pH 1.2 was used as the release medium. The amount of active substance released in each case in the dissolution medium at a specified time was determined by spectrophotometry (at 271 nm). 
     
       
         
               
               
               
             
           
               
                   
               
               
                   
                 Time 
                 Amount of active substance released 
               
               
                   
               
             
             
               
                   
                 15 min 
                 51% 
               
               
                   
                 30 min 
                 80% 
               
               
                   
                 45 min 
                 88% 
               
               
                   
               
             
          
         
       
     
     Example 5 
     5.1. Pellets Produced According to Example 1.1. Were Used 
     5.2. Composition of the Capsule Filling 
     
       
         
               
               
               
               
               
             
           
               
                   
               
             
             
               
                   
                 Pellets produced according 
                 125 
                 mg 
                 95.2% 
               
               
                   
                 to Example 1.1. (≅50 mg 
                   
                   
                   
               
               
                   
                 tramadol) 
                   
                   
                   
               
               
                   
                 Crospovidone, micronized 
                 6.25 
                 mg 
                  4.8% 
               
               
                   
                 Total amount 
                 131.25 
                 mg 
                  100% 
               
               
                   
               
             
          
         
       
     
     Crospovidone (micronized) and pellets were mixed in a high-shear mixer (Diosna Laborgranulator 4) for 15 minutes. The coated pellets were filled in a gelatin capsule of size 0. 
     The breaking strength of the pellets was determined by the method described above, with the apparatus stated there. Breakage did not occur under the action of a force of 500 N. The pellets could not be crushed with a hammer, nor was this possible using a pestle and mortar. 
     The in-vitro release of tramadol from the capsule was determined according to Ph.Eur. in a paddle stirrer with sinker. The temperature of the release medium was 37° C. and the rotary speed of the stirrer was 75 min −1 . 600 ml of buffer pH 1.2 was used as the release medium. The amount of active substance released in each case in the dissolution medium at a specified time was determined by spectrophotometry (at 271 nm). 
     
       
         
               
               
               
             
           
               
                   
               
               
                   
                 Time 
                 Amount of active substance released 
               
               
                   
               
             
             
               
                   
                 15 min 
                 52% 
               
               
                   
                 30 min 
                 77% 
               
               
                   
                 45 min 
                 86% 
               
               
                   
               
             
          
         
       
     
     Example 6 
     6.1. Pellet Production 
     Composition of the Pellets 
     
       
         
               
               
               
             
               
               
               
               
             
           
               
                   
               
               
                   
                 Per capsule filling 
                 Proportion [%] 
               
               
                   
               
             
             
               
                   
               
             
          
           
               
                 Tramadol HCl 
                 50 
                 mg 
                 45% 
               
               
                 Polyethylene oxide 
                 44.4 
                 mg 
                 40% 
               
               
                 7 000 000 (MW) 
                   
                   
                   
               
               
                 (Polyox WSR 303, Dow Chemicals) 
                   
                   
                   
               
               
                 Macrogol 6000 
                 11.1 
                 mg 
                 10% 
               
               
                 (polyethylene glycol 6000 BASF) 
                   
                   
                   
               
               
                 Crospovidone 
                 5.6 
                 mg 
                  5% 
               
               
                   
               
             
          
         
       
     
     The components were weighed and then mixed in a tumbler for 15 minutes. Then they were extruded by means of a twin-screw extruder from the company Leistritz, type ZSE18HP40D with micropelletizer. Eccentric screw tips and a displacer cone were used. The nozzle plate had eight orifices with a diameter of 1.0 mm, with length/diameter ratio of 2.5. Pellet length was 1 mm±20%. The extrusion parameters were as follows: 
     
       
         
               
               
               
             
           
               
                   
               
             
             
               
                   
                 Barrel temperature HZ1 required 40° C./actual: 
                 39.6° C.  
               
               
                   
                 Barrel temperature HZ2 and HZ2 
                 100° C. 
               
               
                   
                 Barrel temperature HZ4 to HZ8 
                 120° C. 
               
               
                   
                 Barrel temperature HZ10 
                 120° C. 
               
               
                   
                 Barrel temperature HZ11 
                 140° C. 
               
               
                   
                 Product temperature in discharge section 
                 134.1° C.   
               
               
                   
                 Discharge rate 
                 33.43 g/min 
               
               
                   
                 Screw speed (1/min) 
                 150/min 
               
               
                   
               
             
          
         
       
     
     The breaking strength of the pellets was determined by the method described above, with the apparatus stated there. Breakage did not occur under the action of a force of 500 N. The pellets could not be crushed with a hammer, nor was this possible using pestle and mortar. 
     6.2. Composition of the Capsule Filling 
     
       
         
               
               
               
               
             
           
               
                   
               
             
             
               
                   
                 Pellets produced according 
                 111 mg 
                 100% 
               
               
                   
                 to Example 6.1. 
                   
                   
               
               
                   
                 (≅50 mg tramadol) 
                   
                   
               
               
                   
                 Total amount 
                 111 mg 
                 100% 
               
               
                   
               
             
          
         
       
     
     The pellets produced according to 6.1. were filled in gelatin two-piece capsules of size 0. The in-vitro release of tramadol from the capsule was determined according to Ph.Eur. in a paddle stirrer with sinker. The temperature of the release medium was 37° C. and the rotary speed of the stirrer was 75 min −1 . 600 ml of buffer pH 1.2 was used as the release medium. The amount of active substance released in each case in the dissolution medium at a specified time was determined by spectrophotometry (at 271 nm). 
     
       
         
               
               
               
             
           
               
                   
               
               
                   
                 Time 
                 Amount of active substance released 
               
               
                   
               
             
             
               
                   
                 15 min 
                 55% 
               
               
                   
                 30 min 
                 77% 
               
               
                   
                 45 min 
                 87% 
               
               
                   
               
             
          
         
       
     
     The foregoing description and examples have been set forth merely to illustrate the invention and are not intended to be limiting. Since modifications of the described embodiments incorporating the spirit and substance of the invention may occur to persons skilled in the art, the invention should be construed broadly to include all variations within the scope of the appended claims and equivalents.